title: Exogenous growth hormone treatment alters body composition and increases natural killer cell activity in women with impaired endogenous growth hormone secretion.
abstract: In order to assess the potential relationship between human growth hormone (GH) and body composition (BC) and natural immunity (NI), we measured the effects of exogenous GH on fat weight (FW), fat-free weight (FFW), and the cytotoxic activity of natural killer (NK) cells in women with impaired GH secretion. Mean peak serum concentrations of GH in response to L-dopa/arginine stimulation were 6.2 +/- 1.1 (SEM) ng/mL in 6 untreated subjects (US) and 5.4 +/- 1.5 ng/mL in 6 GH-treated subjects (TS). Moreover, the pretreatment circulating levels of IGF-I were low in both groups (US 684 +/- 121 mU/mL and TS 583 +/- 83 mU/mL), and they correlated with pretest levels of NK cell activity (r = .59, P less than .05) when both groups were combined. The TS were given 700 micrograms of human GH IM for an average of 14 days while the US were studied in parallel without GH treatment. As measured by hydrodensitometry or skinfold anthropometry, FW decreased (26.1 +/- 6.8 kg to 23.8 +/- 6.3 kg, P less than .05) and FFW increased (44.9 +/- 3.3 kg to 46.2 +/- 3.8 kg, P less than .05) in the TS. In the US, there were no significant (P less than .05) changes in either FW or FFW. Using a standard 51Cr release assay to measure the specific lytic (SL) activity of NK cells, mean SL activity increased from 24.4 +/- 7.0% to 44.1 +/- 8.9% (P less than .05) in the TS, whereas levels in the US were not altered significantly (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Medicine, University of New Mexico School of Medicine, Albuquerque 87131.
authors: D M
authors: DM
authors: Crist
authors: G T
authors: GT
authors: Peake
authors: L T
authors: LT
authors: Mackinnon
authors: W L
authors: WL
authors: Sibbitt
authors: J C
authors: JC
authors: Kraner
mesh_terms: D000328:Adult; D001120:Arginine; D001823:Body Composition / Q000187:drug effects*; D005260:Female; D013006:Growth Hormone / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency*; D007694:Killer Cells, Natural / Q000187:drug effects*; D007980:Levodopa; D013002:Somatomedins / Q000172:deficiency*
chemical_list: D013002:Somatomedins; D007980:Levodopa; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D001120:Arginine